Epigral
Epigral Q1 FY27 Results & Concall Highlights: Revenue, Margins & Order Book
Q1 FY27 earnings call: what management guided on revenue, margins and order book.
What the Q1 FY27 call signalled
3 of 4 strong
Not discussed on this call: order book.
The short version
Epigral targets a CAGR growth of 15% to 20% in both top line (sales/revenue) and bottom line over the next 3 to 5 years. Epigral targets a compound annual growth rate (CAGR) of 15% to 20% for both top-line and bottom-line over the next 3 to 5 years, driven by ramp-up of new capacities and growing market demand.
From Epigral's Q1 FY27 earnings-call transcript · updated 25 Aug 2026.
Revenue & Sales Performance
- Epigral targets a CAGR growth of 15% to 20% in both top line (sales/revenue) and bottom line over the next 3 to 5 years.
- Growth driven by ramping up existing capacities (chlorotoluenes, caustic soda, CPVC) and commissioning new capacities such as Epoxy Resin, Epichlorohydrin (ECH), and multipurpose plants.
- The company aims to expand from approximately INR2,500 crores current revenue to around INR3,000-3,500 crores in the near term, and with all plants at optimal utilization, the top line could reach INR4,000+ crores over time.
- Domestic demand, especially in infrastructure, renewable energy, automotive, and pharmaceutical/agrochemical intermediates, is expected to sustain double-digit volume growth.
- Long-term focus includes capturing growing Indian market demand and eventual exports, especially to Europe post-FTA agreements.
- Expectation of margin stability around 22%-25% with a 3-4 year gestation to reach peak utilization for new projects.
Profitability & Margins
See what Epigral said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Epigral Limited has approved a strategic capex plan for two new projects:
- - Epoxy Resin & Formulations plant with 125,000 tons per annum capacity.
- - A Multipurpose Plant (MPP) to manufacture downstream products of epichlorohydrin and chlorotoluenes value chain.
- Total capex in chlorotoluenes around INR 250 crores has been done.
- Combined peak revenue expected post these projects is INR 1,300 to 1,500 crores.
- Overall capex including the MPP is expected to result in consolidated top line in the range of INR 700 to 800 crores initially.
- Capex split: 40% internal accruals, 60% debt.
- Estimated EBITDA margin for chlorotoluenes/MPP around 22%-23%.
- Gestation/ramp-up period expected to be 1.5 to 2 years for optimum utilization.
- A pilot plant for epoxy resin and MPP is to be operational by Q2 FY27 for product and customer approvals.
Top-ranked in Chemicals & Petrochemicals
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Epigral said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
Epigral — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹736 Cr, net profit ₹82 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Epigral Ltd's management said in earlier quarters
Others in Chemicals & Petrochemicals this season
- Solar Industries India Ltd (Q1 FY27)
EBITDA margin improvement potential in explosive business to reach mid-teens (18-19% global benchmarks), with combined Solar-BME margins currently at 13-14%…
- Sudarshan Chemical Industries Ltd (Q1 FY27)
The net debt has already been reduced significantly from Rs.922 Crores at acquisition to Rs.531 Crores. Key concall takeaways from Sudarshan Chemical…
- Indo Borax & Chemicals Ltd (Q1 FY27)
250-260 crores in FY27 with about 20% EBITDA margin, growing at 11-12% annually in absolute terms. Key concall takeaways from Indo Borax & Chemicals Ltd's Q1…
- SRF Ltd (Q1 FY27)
Chemicals business is guided for 15-20% growth in FY27, with a strong Q1 performance positioning the company to possibly hit the higher end of this range (Page…
Frequently Asked Questions
What were Epigral Q1 FY27 results?
Epigral targets a CAGR growth of 15% to 20% in both top line (sales/revenue) and bottom line over the next 3 to 5 years. Epigral targets a compound annual growth rate (CAGR) of 15% to 20% for both top-line and bottom-line over the next 3 to 5 years, driven by ramp-up of new capacities and growing market demand.
What is Epigral share price analysis?
Epigral currently shows a moderate growth signal based on ranking data. The stock trades at a P/E of 17.9 with a market cap of ₹4,858 Cr. Investors should review the full earnings analysis for detailed insights.
Is Epigral planning capital expenditure?
Epigral Limited has approved a strategic capex plan for two new projects: - Epoxy Resin & Formulations plant with 125,000 tons per annum capacity.
Keep Epigral on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.